Table 2.
Primary and Secondary Outcomes by Treatment Group
| Fidaxomicin (n = 38) | Vancomycin (n = 200) | Total (N = 238) | |
|---|---|---|---|
| Primary outcome: compositea | 4 (10.5) | 38 (19.0) | 42 (17.6) |
| Secondary outcomes | |||
| Clinical failure | 2 (5.3) | 4 (2.0) | 6 (2.5) |
| Relapse | |||
| 30 db | 1 (2.9) | 25 (13.4) | 26 (11.7) |
| 90 dc | 2 (5.9) | 14 (8.6) | 16 (8.2) |
| Total | 3 (8.6) | 39 (20.9) | 42 (18.9) |
| Death related to CDI | 1 (2.6) | 9 (4.6) | 10 (4.3) |
| Other causes of death | 5 (13.2) | 7 (3.5) | 12 (5.0) |
Abbreviation: CDI, Clostridioides difficile infection.
Data are presented as No. (%).
aComposite outcome: clinical failure, relapse at 30 days, and death related to CDI.
bAfter exclusion of patients who died (n = 222).
cAfter exclusion of patients who had clinical failure, died, or had 30-day relapse (n = 196).